Taiga Biotechnologies

Biotechnology ResearchColorado, United States0-1 Employees

Taiga Biotechnologies is a clinical-stage biotechnology company based in Aurora, Colorado, focused on leveraging the immune system to combat solid tumors and infectious diseases, and on improving outcomes in blood stem cell transplantation. The company pursues immunotherapy programs to temporarily boost immune function in healthy individuals and regenerative medicine approaches to generate a new, healthy immune system for patients with compromised immunity. Its lead cell-based immunotherapy candidate, TBX-3400, uses a patient’s own peripheral blood mononuclear cells that are treated outside the body with a fusion protein and delivered intravenously the following day. The approach emphasizes the use of autologous cells for cancer and infection without genetic modification or in vitro expansion requirements. 

Taiga is advancing a Bone Marrow Engraftment Enhancer program, TBX-2400, designed to improve engraftment of hematopoietic stem and progenitor cells during allogeneic hematopoietic stem cell transplant procedures. The BMEE program aims to increase the likelihood of successful engraftment, accelerate reconstitution of mature lymphocytes, and mitigate transplantation-related complications, supporting longer-term survival for transplant patients. The company operates within the biotechnology research sector, positioning its work at the intersection of immunotherapy and regenerative medicine for immune-related conditions.

Sign up for free to view info

Email Format Employee directory